Consult the summary of product characteristics for details of authorised indications of each SSRI.
| SSRIs: Approved names, common proprietary names and licensed indications | ||||||||
| Selective serotonin reuptake inhibitor (SSRI) | Common proprietory names | Depressive illness | Generalised anxiety disorder | Obsessive–compulsive disorder | Panic disorder with or without agoraphobia | Social anxiety disorder (social phobia) | Post-traumatic stress disorder | Bulimia nervosa |
| Citalopram | Cipramil |  |
|
|||||
|
Escitalopram |
Cipralex | |
|
|
|
|
||
| Fluoxetine | Prozac | |
|
|
||||
| Fluvoxamine | Faverin | |
|
|||||
| Paroxetine | Seroxat | |
|
|
|
|
|
|
| Sertraline | Lustral | |
|
|
|
|
||
Antidepressants in other classes may also inhibit reuptake of serotonin, but only SSRIs are discussed here.
Only the following SSRIs are licensed for children and adolescents:
- Fluoxetine for the treatment of moderate to severe major depressive episode (in combination with psychological therapy) in children aged over eight years and adolescents
- Fluvoxamine for the treatment of obsessive–compulsive disorder in children aged over eight years and adolescents
- Sertraline for the treatment of obsessive–compulsive disorder in children aged over six years and adolescents.
< Previous pageNext page >Section 1 (Page 2 of 3)
